Qube Research & Technologies LTD Cti Biopharma Corp Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $253,927 - $363,358	60,459 New	60,459 $253,000
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $576,196 - $1.02 Million	-162,309 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$1.9 - $5.23 $236,897 - $652,092	124,683 Added 331.37%	162,309 $758,000
Q4 2021 Feb 01, 2022	BUY	$1.44 - $2.86 $18,630 - $37,002	12,938 Added 52.41%	37,626 $93,000
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.18 $55,548 - $78,507	24,688 New	24,688 $73,000
Q2 2021 Aug 13, 2021	SELL	$2.16 - $2.62 $89,840 - $108,973	-41,593 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.68 - $3.8 $345,693 - $490,162	-128,990 Reduced 75.62%	41,593 $121,000
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $423,045 - $648,215	170,583 New	170,583 $549,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.